2023-11-28 07:35:29 ET
DENVER, Colo., Nov 28, 2023 ( www.247marketnews.com )- Avidity Biosciences, Inc. (NASDAQ: RNA) reported, this morning, that it expanded its global licensing and research collaboration with Bristol Myers Squibb (NYSE: BMY) fixated on discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity’s proprietary AOC platform technology. The agreement calls on Avidity to receive $100 million up front with the potential to receive up to $2.2 billion in milestone payments and up to low double-digit royalties
Avidity Biosciences is trading at $8.19, up $2.03 (+32.95%), on 357.7K premarket shares.
Its 52-week range is $4.825 to $25.74. It’s been in an uptrend since hitting its 52-week low late October and is in a trading range that it last saw …
The post Expansion of Cardiovascular Collaboration with Bristol Myers Squibb has this Company’s Heart Beating appeared first on 24/7 market News .
For further details see:
Expansion of Cardiovascular Collaboration with Bristol Myers Squibb has this Company’s Heart Beating